Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 5/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456472 | 0.83 | FADS1 (0.36) | FADS1ALDH1A1HSP90AA1HTTKMT2A | |
| SCHEMBL23456467 | 0.80 | NPC1 (0.34) | FADS1ENPP1ENPP3ALDH1A1HTT | |
| SCHEMBL23414973 | 0.78 | FADS1 (0.52) | FADS1ENPP1ENPP3ALDH1A1KMT2A | |
| SCHEMBL23414942 | 0.75 | FADS1 (0.54) | FADS1ENPP1ENPP3ALDH1A1KMT2A | |
| SCHEMBL23456485 | 0.74 | FADS1 (0.51) | FADS1ALDH1A1HSP90AA1HTTKMT2A | |
| SCHEMBL23456464 | 0.74 | PARP1 (0.35) | ALDH1A1HSP90AA1HTTKMT2ANPSR1 | |
| SCHEMBL23414877 | 0.72 | FADS1 (0.52) | FADS1ALDH1A1HTTKMT2ANPSR1 | |
| SCHEMBL23415032 | 0.70 | FADS1 (0.38) | FADS1ALDH1A1HSP90AA1HTTKMT2A | |
| SCHEMBL23456499 | 0.70 | FADS1 (0.43) | FADS1HTTTDP1 | |
| SCHEMBL21623716 | 0.70 | ENPP3 (0.32) | ENPP1ENPP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | FADS1 5/4885ENPP1 588/4885ENPP3 834/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | FADS1 5/4885ENPP1 588/4885ENPP3 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.